osomal siRNA. VEGFR2 inhibition resulted in an increase in intratumoral distribution 23 and therapeutic efficacy despite the maturation of the tumor vasculature. A small mole-24 cule inhibitor against matrix metalloproteinase and macrophage depletion canceled the 25 improvement in the distribution of the LNPs, suggesting that remodeling of tumor mi-26 croenvironment played a role in the facilitated intratumoral distribution via the 27 down-regulation of VEGFR2. Accordingly, our results suggest that the EPR effect is 28 dependent, not only on the structure of the tumor vasculature, but also on the dynamics 29 of the tumor microenvironment including extracellular matrix remodeling. Regulating 30 the tumor microenvironment and the extracellular matrix by delivering tumor endothe-31 lial cell-targeting siRNA could potentiate the EPR effect-based strategy.
Introduction 33
Over the past decades, a number of groups have reported on the development of 34 tumor-targeting nanoparticles, most of which function based on the enhanced permea-35 bility and retention (EPR) effect. 1 The EPR effect involves the systemic injection of 36 macromolecules with a long circulation time that can passively accumulate in tumor 37 tissue because the high levels of vascular endothelial growth factor (VEGF) in tumor 38 tissue makes the vasculature porous and leaky. 2 On the other hand, recent studies re-39 vealed that components of the extracellular matrix (ECMs), such as collagen and hya-40 luronan, are major obstacles to the intratumoral diffusion of cancer-targeted nanoparti-41 cles. 3 The high density of cells, in addition to abundant ECMs in tumor tissue, results in 42 an elevated interstitial fluid pressure (IFP), which is inverse from the extracellular space 43 to the capillary. 4 Additionally, these ECMs sterically hinder the diffusion of nanoparti-44 cles. In fact, it has been shown that the enzymatic degradation of these components by 45 collagenase or hyaluronidase treatment resulted in the improved delivery of nano-sized 46 therapeutics. 5, 6 The effect of ECMs would be predicted to be proportional to the size of 47 nanoparticles. Cabral H et al. recently confirmed this, by showing that small-sized nanoparticles with a diameter of 30 nm penetrated more deeply into tumor tissue than 49 large-sized nanoparticles with a diameters of 100 nm in a hypovascular cancer model. 7 
50
These collective findings indicate that ECMs severely restrict the intratumoral distribu-51 tion of 100 nm nanoparticles. Accordingly, regulating tumor microenvironment includ-52
ing abnormal vasculature and ECMs should be required for further development of 53 cancer-targeted nano medicines. Nowadays, a much attention has been paid for control-54 ling tumor microenvironment for a more efficient cancer targeting. 8, 9 55 Recently, we accidentally discovered that an inhibition of VEGF signaling in the 56 tumor endothelial cells (TECs) by siRNA unexpectedly elevated an accumulation and 57 an intratumoral distribution of nanoparticles in human renal cell carcinomas (RCCs), 58 which is known to be a highly vascularized cancer.
10
This improvement must be unex-59 plainable through the basis of EPR effect that the malformed vasculature is responsible 60 for EPR-based delivery. In this manuscript, we tried to elucidate the mechanism on this 61 unknown increase in the accumulation and intratumoral distribution of nanoparticles. 62
Our hypothesis is as follows; 1) VEGF signaling abnormally overexpressed in TECs is 63 inhibited by siRNA, 2) TECs regulated by siRNA attracts some cell population, 3) Theattracted cell population degrades ECMs by some proteases, 4) This series of phenomenon after the inhibition in VEGF signaling alters tumor microenvironment for an ap-66 propriate distribution of nanoparticles. 67
To prove our hypothesis, we examined the effect of VEGF receptor 2 (VEGFR2) 68 inhibition on the intratumoral distribution of lipid nanoparticles (LNPs) and the dynam-69 ics of ECMs in highly vascularized cancer RCCs. For the in situ down-regulation of a 70 specific gene on TECs, we used a cyclic RGD-modified liposomal siRNA 71 (RGD-MEND). This is because delivering a siRNA specifically to TECs circumvents 72 off-target effects in other cells such as cancer cells and stromal cells, indicating that a 73 small molecule or an antibody can affect the function of other cell populations. In addi-74 tion, the RGD-MEND had no effect on endothelial cells in normal organs.
11

Therefore, 75
we were able to analyze the effect of gene silencing exclusively in TECs. The lipid en-76 velope of the RGD-MEND was composed of YSK05, a pH-sensitive cationic lipid. The 77 acid dissociation constant, pKa, of YSK05 is approximately 6.5, which allows 78 YSK05-containing liposomes to be biocompatible in the blood stream, where the pH is 79 maintained at 7.4. In addition, the positive charge under acidic conditions resulted in 80 efficient membrane fusion after the internalization of the particles by cells. This ex-81 plains why YSK05-conatining MENDs are able to deliver siRNA and suppress a gene 82 of interest in hepatocytes, tumor tissue. 12, 13 In this study, cyclic RGD, which recognizes 83 the α V β 3 integrin heterodimer, was used as a specific ligand for TECs that express high 84 levels of α V β 3 integrin. 14 Owing to these functional devices, the RGD-MEND had the 85 ability to inhibit a TEC gene at a dose of 0.75 mg siRNA/kg.
11, 15
86
We investigated the alteration in the intratumoral distribution of nano DDSs and the 87 tumor microenvironment after vasculature maturation via the inhibition of VEGFR2 on 88
TECs by the RGD-MEND. Our results suggest that vasculature leakiness as the result of 89 immature vessels is not necessarily required for the extravasation of LNPs, at least in 90 hypervascular cancer, and that carefully controlling the tumor microenvironment, in-91
cluding ECMs, has the potential for maximizing the therapeutic effect of nanoparticles. 92
Results 94
VEGFR2 knockdown and consequent changes of intratumoral distribution 95
We first examined the silencing efficacy of RGD-MEND encapsulating siRNA against 96 murine VEGFR2 (si-VR2) with human RCC, OS-RC-2-bearing mice. RCCs are char-97 acterized as a highly vascularized form of cancer, mainly due to the excessive amount 98 of VEGF that is produced, due to the von Hippel Lindau factor is absent.
16
The LNPs 99 used contained the pH-sensitive lipid, YSK05, and details of their characterization are 100 shown in Supplemental Figure 1) . Injection of the RGD-MEND significantly inhibited 101 VEGFR2 expression in terms of both the mRNA and protein level (Supplemental Figure  102 2a-c). A single injection of the RGD-MEND partially succeeded in improving penetra-103 tion of the LNPs, but that was observed only in a small area of the tumor tissue by con-104 focal laser scanning microscopy (CLSM) (Supplemental Figure 3) . We speculated that a 105 level of VEGFR2 knockdown is not sufficient and too short to alter the tumor microen-106 vironment. This is because VEGFR2 dissipated rapidly because the TECs grew more 107 rapidly than normal cells.
17
In non-proliferative tissues, such as the liver, gene silencing 108 is observed, at least, for a week.
18
The concentration of siRNA would be diluted by the 109 rapid proliferation. Therefore, we administered si-VR2 encapsulated in the 110 RGD-MEND continuously over a period of 4 days. CLSM revealed that the distribution 111 of the LNPs was obviously altered and the distribution was increased by 1.9-fold as the 112 result of a pre-treatment with the RGD-MEND (Fig. 1b, c) . Further, the improvement in 113 intratumoral distribution was reproducible despite the short-lived knockdown of 114 VEGFR2 (Supplemental Figure 2a) . The improvement appeared to be achieved when 115 the concentration of VEGFR2 was sufficiently decreased for a certain time. To quantita-116 tively measure the intratumoral distribution, single cancer cells from tumor tissues were 117 subjected to fluorescence-activated cell sorting (FACS, Supplemental Figure 4 ). The 118 fluorescence intensity of the LNPs were increased by 2.1-fold and the coefficient of 119 valiance (CV) was decreased ( Fig. 1d-e) . In addition, not only the distribution but also 120 level of accumulation was significantly augmented (Fig. 1f) . On the other hand, particle 121 accumulation in normal organs was not changed except for the spleen (Supplemental 122 Figure 5 ). In addition, when a control siRNA was assembled in the RGD-MEND, the 123 intratumoral distribution of LNPs was not altered (Supplemental Figure 6) . It is possible 124 that the increased accumulation of LNPs (Figure 1f ) could be attributed to the widened 125 intratumoral distribution of LNPs. However, a 2.67-fold increase in the amount of sys-126 temically administered LNPs failed to result in the broad intratumoral distribution of 127 LNPs (Supplemental Figure 7) . Therefore, another factor aside from the elevated accu-128 mulation of LNP appears to be responsible for the increased intratumoral accumulation. 129
To assess the impact of improving the intratumoral distribution of LNPs on therapeu-130 tic efficacy, OS-RC-2-bearing mice were administered doxorubicin-loaded liposomes 131
(DOX-LNP, characterized in Supplemental Figure 1 ) and an RGD-MEND encapsulat-132 ing si-VR2 at the same time. As a result, only the co-injection resulted in a substantial 133 inhibition of tumor growth (Fig. 1g) . Incidentally, only the injection of the RGD-MEND 134 led to a moderate inhibition of tumor growth. This suppression was interpreted as being 135 due to the anti-angiogenic effect of VEGFR2 inhibition via the delivery of siRNA to 136
TECs. We previously confirmed that an RGD-MEND encapsulating si-VR2 caused a 137 delay in tumor growth by decreasing the density of microvessels in tumor tissue. resulted in an increase in vasculature stained by both isolectins, suggesting that the 160 blood flow was recovered as the result of injecting the RGD-MEND (Fig. 2f, g ). These 161 results show that delivering siRNA by the RGD-MEND led to vascular maturation in 162 terms of both structure and function, and also implies that the maturation of the tumor 163 vasculature did not necessarily inhibit the extravasation and distribution of large nano-164 particles (100 nm). 
Altering nanoparticle distribution by macrophages through ECM degradation 197
We then attempted to identify which cell population produced MMPs. In tumor tis-198 sues, macrophages are a major source of MMPs. were completely removed (Supplemental fig. 11 ). LNPs and formulated si-VR2 were 211 systemically administered to OS-RC-2 bearing mice with or without L-clondronate. 212
LNPs were more broadly distributed in the presence of L-clondronate ( fig. 4c, d ). At 213 this time L-clondronate significantly increased the levels of COL1A1 ( fig. 4e, f) . Ac-214 cordingly, macrophages infiltrating into tumor tissues by the injection for RGD-MEND 215 produced MMPs, and ECMs were subsequently broken down. In such a tumor micro-216 environment, LNPs would be able to readily diffuse into the tumor mass. 217
Discussion 219
The EPR effect is attributed to abnormal tumor vasculature with leaky intercellular 220 junctions and intracellular fenestrae owing to overexpressed VEGF (<30-fold) in tumor 221 tissue. 24, 25 In fact, inflammatory factors, such as bradykinin and nitric oxide, facilitated 222 the extravasation of the pigment, Evans Blue. 5 shows a summary of our study. 228
It is known that VEGFR2 is a major protein in primary angiogenesis in tumor tis-229 sue, and thus blocking the action of VEGFR2 would result in the inhibition of tumor 230 growth via the anti-angiogenic effect.
27, 28
The relationship, however, between VEGFR2 231 and ECMs in the tumor tissue is not well-validated. On the other hand, abundant ECMs 232 are a typical symptom for fibrotic diseases in non-cancerous tissues, such as cirrhosis of 233 the liver. In the case of normal organs, it was known that VEGFR2 plays a pivotal rolein the progression of fibrosis, and the inhibition of VEGFR2 ameliorates fibrosis. 29, 30 In 235 addition, VEGFR2 inhibition was also reported to improve renal fibrosis in a fibrosis 236
Although the exact mechanism responsible for the decomposition by blocking 237 the action of VEGFR2 is not understood, some reports have indicated that MMPs are 238 involved.
32
Our hypothesis seems to be consistent with these results on the involvement 239 between hepatic and renal fibrosis and VEGFR2. 240
Several studies have reported that reagents, such as bradikynin Besides, pericyte coverage and collagen degradation was increased in a siR-257 NA-dose dependent manner (Figure 2c and 3b) . This dose-dependency suggests that 258 altering tumor microenvironment would depend on an extent of VEGFR2 inhibition. 259 Therefore, more frequent injections or an increase in the amount of siRNA would result 260 in a more robust silencing of VEGFR2, and therefore more efficacious improvement in 261 the distribution of large nanoparticles. 262
The suppression of VEGFR2 by si-VR2 evoked the infiltration of macrophages, and 263 the subsequent ECMs degradation of MMPs by macrophages ( fig. 4a, e) . Thus, LNPs 264 were able to deeply penetrate into tumor tissue. This infiltration can be attributed to the 265 fact that the inhibition of VEGFR2 on endothelial cells forced them to produce some 266 types of cytokines or chemokines that are attracted to monocytes in the blood stream. A 267 previous report by Kroepper et al. also suggested that inhibiting VEGFR2 by an anti-268 body increased the levels of macrophages in a glioblastoma model, specifically M1-like 269 phenotypes. 35 However, these investigators did not conclude that VEGFR2 was a factor 270 in attracting M1 macrophages after treatment with a VEGFR2 antibody. The relation-271 ship between VEGF signaling and the tumor microenvironment including macrophages 272 currently remains unclear. Further study will be needed to achieve an understanding of 273 the involvement of macrophages on anti-angiogenic therapy and our strategy. 274 However, macrophage infiltration is known to be an indicator of metastasis and a 275 poor prognosis in patients.
36
Specifically M2 macrophages are immunosuppressive and 276 support the proliferation of cancer cells, while M1 macrophages play a role in the an-277 ti-tumor effect by supporting immunoresponse. 37 We then determined the phenotypes of 278 the induced macrophages by measuring M1 marker genes (inducible NO synthase (iN-279 OS), Cxcl-9, IL-1β, IL-6 and TNF-α) and M2 marker genes (mannose receptor C, type I 280 (MMR and Arginase-1) (Supplemental Figure 11) . In the case of M1 markers, Cxcl-9 281 and TNF-α were significantly increased while, in the case of M2 markers, MMR andArginase-1 were decreased. This result suggests that macrophages induced by the injec-283 tion of the RGD-MEND are M1-like macrophages. That is consistent with previous re-284 ports, in which the injection of an anti-VEGFR2 antibody DC101 evoked the produc-285 tion of M1-like macrophages, and consequently potentiated the efficacy of immunoad-286 juvant therapy.
38
In addition, M1 macrophages supported an autoimmune system to ex-287 clude cancer cells. 39 Therefore, M1 macrophages elevation in our strategy would not 288 induce a progress in infiltration and metastasis of cancer cells. 289
There is a possibility that siRNA was recognized by toll-like receptors (TLRs) 3, 7 or 290 8, 40 and thus macrophages were attracted by produced cytokines via immunostimulation 291 of siRNA, not by VEGFR2 inhibition. We examined the immune reaction by the siRNA 292 used in this study to exclude this possibility. To assess the immune response caused by 293 the RGD-MEND encapsulating siRNA against VEGFR2 itself, we measured the pres-294 ence of an interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which 295 was previously reported as a marker gene for an immune response to the presence of 296 siRNA. 41 The findings indicated that IFIT1 was not changed by the RGD-MEND injec-297 tion (Supplemental Figure 12) tive control) were also tested. As a result, the chemically modified si-VR2 used in this 301 study failed to induce an immune response after its systemic injection. This result sug-302 gests that the immune response by the formulated siRNA did not contribute to the infil-303 tration of macrophages, and that the inhibition of VEGFR2 itself induced the infiltration 304 of macrophages. Losartan, on the penetration of intratumorally injected herpes simplex virus (HSV). 43 
310
The Losartan treatment drastically improved the intratumoral penetration of HSV, ac-311 companied by the inhibition of TGF- production and subsequent decrease in type I 312 collagen levels. The same group also reported that this decrease in collagen content was 313 the result of the deactivation of cancer-associated fibroblasts (CAFs) via the inhibitionof the angiotensin II receptor- 1. 44 These studies suggest that the stiffness of ECMs are 315 important factors in the tumor penetration of nanoparticles, as opposed to vessel struc-316 ture. Likewise, a si-VR2 treatment induced the degradation type 1 collagen due to the 317 activation of MMPs ( fig. 3a, d) . The improved intratumoral distribution of LNPs could 318 be caused by an increase in vascular dynamics through the infiltration of macrophages 319 and the subsequent remodeling of vessels and/or ECMs. On the other hand, the produc-320 tion of high levels of MMPs is also known to facilitate metastasis via the degradation of 321 the basement membrane around the vasculature.
45
If the basement membrane was de-322 graded, cancer cell readily intravasate. Thus, MMPs production increased a risk for 323 progression of cancer because intravasation is the first step of metastasis.
46
Based on 324 these previous reports, it is possible that the injection of the RGD-MEND might also 325 promote metastasis from a primary tumor in our strategy. However, type IV collagen 326 was not changed after the RGD-MEND treatment (Supplemental figure 9) . This means 327 that the increased MMPs are not likely involved in the degradation of the basement 328 membrane, and consequently that increased MMPs didn't allow cancer cells to intrava-329 sate. Taken together, the improvement in intratumoral distribution through the inhibition 330 of VEGFR2 by the RGD-MEND does not appear to be a risk factor for cancer metasta-331 sis. For developing this strategy, the effect of si-VR2 treatment on progression and/or 332 metastasis should be investigated. 333
In this study, we show that the siRNA-mediated alteration in structural properties 334 of the tumor vasculature and tumor microenvironment improved the distribution of 335
LNPs, which results in a synergistic therapeutic effect when 100 nm DOX-LNP parti-336 cles were used. As mentioned in the introduction section, small nanoparticles (<30 nm) 337 have been found to easily extravasate and penetrate in tumor tissue deeply, whereas 338 large nanoparticles (>100 nm) cannot.
7
This means that relatively large nanoparticles 339
are not applicable for use in EPR-based nanotherapeutics. On the other hand, our find-340 ings suggest that regulating the tumor microenvironment via inhibiting VEGFR2 allows 341 even large nanoparticles to extravasate and diffuse in tumor tissue. In short, the results 342
show that relatively large nanoparticles (>100 nm) can be use in the above processes, 343 thus expanding the spectrum of available nano DDSs. 344
The fact that the dynamics of the tumor vasculature and ECMs remodeling had a huge 345 impact on the accumulation of LNPs raised some questions about the EPR effect-basedstrategy as a static phenomenon. It should, however, be noted that we have no perspec-347 tive regarding with which types of cancers the improvement of nanoparticles could be 348 induced by blockade in VEGF signaling. A previous study suggested that tumor vascu-349 lature phenotypes defined VEGF sensitivity. MO, USA). SiRNA was synthesized by Hokkaido System Sciences (Sapporo, Japan). 364
High-Capacity RNA-to-cDNA kit and Quanti-iT RiboGreen were purchased from 365
ThermoFisher SCIENTIFIC (Waltham, MA, USA). THUNDERBIRD SYBR qPCR 366
Mix was purchased from TOYOBO (Osaka, Japan). Hoechst33342 was purchased from 367 DOJINDO (Kumamoto, Japan). Chlondronate liposome was obtained from FormuMax 368 (Palo Alto, CA, USA). Polyehtyleneglycol-dimyristoyl-glycerol (PEG-DMG), Poly-369 ehtyleneglycol-distearoyl-glycerol (PEG-DSG) and dis-370 tearoyl-sn-glycerophosphocholine (DSPC) were purchased from the NOF CORPORA-371 TION (Tokyo, Japan). OCT compound was obtained from Sakura Finetek Japan (Tokyo, 372 Japan). Cyclic RGD was sysnthesized by Peptides international (Louisville, KY, USA). 373
Lipidic fluorescent dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine A human renal cell carcinoma cell line, OS-RC-2 cells were cultured in RPMI 1640 387 supplemented with 10% fetal bovine serum (FBS) and penicillin (100 U/ml), strepto-388 mycin (100 μg/ml) at 37°C under a 5% CO2 humidified atomosphere. BALB/c nude 389 mice were purchased from CLEA Japan Inc. (Shizuoka, Japan). To prepare tu-390 mor-bearing mice, athymic mice were injected with 1×10 LNPs encapsulating siRNA was prepared by the tertiary butyl alcohol (t-BuOH) dilu-398 tion method, as previously reported.
13, 48
Lipids (3,000 nmol, 399 YSK05/cholesterol/PEG-DMG, 70/30/3, molar ratio) in 400 L of t-BuOH were gradu-400 ally added to a siRNA solution, and the mixture was then added stepwise to 2.0 mL of 401 citrate buffer (pH 4.0). The diluted mixture was rapidly added to 4.0 mL of PBS (−), 402 and was then subjected to ultrafiltration by means of a Vivaspin (Sartorius Stedim Bio-403 tech, Goettingen, German: MWCO 100,000 Da) twice. This carrier has already been 404
shown to accumulate in cancer cells, as previously reported. (NHS-PEG2000-DSPE) (cRGD-PEG) was used. LNPs were modified with cRGD-PEGby incubating them for 30 min at 60°C in 7.5% of ethanol. After the incubation, the 409 mixture was ultrafiltered by Vivaspin. Thus, the prepared RGD-MEND was able to de-410 liver siRNA specifically to tumor endothelial cells. 
Preparation of DOX-LPs 417
Doxorubicin-loaded nanoparticles were prepared by a pH-loading method as previously 418 reported.
48
Lipid thin films (4,000 nmol, DSPC/cholesterol/PEG-DSPE, 50/50/5, molar 419 ratio) were prepared in glass tubes, and 500 L of ammonium sulfate buffer (300 mM, 420 pH 4.5) was then added. The glass tubes were sonicated for 30 sec in a bath-type soni-421 cator (AU-25C, Aiwa Co., Tokyo, Japan)) and then for 10 min with a probe-type soni-422 cator (Misonix, Farmingdale, NY, USA). The sonicated colloidal solution was then cen-423 trifuged (15,000 rpm, 10 min, room temperature) three times to remove debris at a sonication step. The supernatant was mixed with 200 g of doxorubicin, and then incubated9. 
